Literature DB >> 11489243

Immunotherapy for prostate cancer.

B I Rini1, E J Small.   

Abstract

The components of an effective immune response have been elucidated in recent years. An understanding of the dysfunction of the immune response in cancer in one or more of these components has led to a variety of immunotherapeutic approaches. These therapeutic strategies are designed to stimulate dendritic cell proliferation, promote antigen uptake and processing, stimulate an effector cell response via direct antigen presentation, or target tumor cells via antibody therapy. Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489243     DOI: 10.1007/s11912-001-0028-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  21 in total

1.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Authors:  E J Small; P Fratesi; D M Reese; G Strang; R Laus; M V Peshwa; F H Valone
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

2.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Authors:  M G Sanda; D C Smith; L G Charles; C Hwang; K J Pienta; J Schlom; D Milenic; D Panicali; J E Montie
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

3.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

Authors:  D I Gabrilovich; T Ishida; S Nadaf; J E Ohm; D P Carbone
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

5.  Follow-up evaluation of a phase II prostate cancer vaccine trial.

Authors:  B A Tjoa; S J Simmons; A Elgamal; M Rogers; H Ragde; G M Kenny; M J Troychak; A L Boynton; G P Murphy
Journal:  Prostate       Date:  1999-07-01       Impact factor: 4.104

6.  GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.

Authors:  S J Simmons; B A Tjoa; M Rogers; A Elgamal; G M Kenny; H Ragde; M J Troychak; A L Boynton; G P Murphy
Journal:  Prostate       Date:  1999-06-01       Impact factor: 4.104

7.  Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

Authors:  M Mincheff; S Tchakarov; S Zoubak; D Loukinov; C Botev; I Altankova; G Georgiev; S Petrov; H T Meryman
Journal:  Eur Urol       Date:  2000-08       Impact factor: 20.096

8.  Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.

Authors:  S F Slovin; H I Scher; C R Divgi; V Reuter; G Sgouros; M Moore; K Weingard; R Pettengall; M Imbriaco; A El-Shirbiny; R Finn; J Bronstein; C Brett; D Milenic; A Dnistrian; L Shapiro; J Schlom; S M Larson
Journal:  Clin Cancer Res       Date:  1998-03       Impact factor: 12.531

9.  Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.

Authors:  R F Meredith; A J Bueschen; M B Khazaeli; W E Plott; W E Grizzle; R H Wheeler; J Schlom; C D Russell; T Liu; A F LoBuglio
Journal:  J Nucl Med       Date:  1994-06       Impact factor: 10.057

10.  Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172).

Authors:  D Hrouda; B Baban; W D Dunsmuir; R S Kirby; A G Dalgleish
Journal:  Br J Urol       Date:  1998-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.